Literature DB >> 9582015

TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer.

R Erber1, C Conradt, N Homann, C Enders, M Finckh, A Dietz, H Weidauer, F X Bosch.   

Abstract

Recent studies have suggested that different mutation types within the core domain of the tumour suppressor protein p53, i.e. DNA contact mutations and structural mutations, confer different biological properties. We have analysed in 86 head and neck squamous cell carcinomas (HNSCC), whether these p53 mutation types have a differential clinical impact. Thirty-seven missense mutations were identified. Thirteen of these (36%) were DNA contact mutations, occurring in the L3 loop, in the H2 loop sheet helix motif, in the S10 beta strand and in Zinc binding residues. Microsatellite marker analysis revealed a selective association between these mutations and the loss of wild-type alleles (100% LOH vs 50% LOH in tumours with structural mutations; P=0.0034, Fisher's exact, 2-tailed). In comparison to structural mutations or to the absence of mutations in the core domain, DNA contact mutations were associated with higher tumour stages (84.6% vs 62%), a higher incidence of lymph node metastasis (91.7% vs 56%; P=0.014, Fisher's exact, 2-tailed), a shortened recurrence-free survival (8.1 months vs 23.7 months, P=0.047, log rank test) and overall survival (11 months vs 29.2 months; P=0.003, log rank test). The latter was also the case when only stage IV tumours were analysed (P=0.0055, log rank test). These data indicate that in HNSCC, TP53 DNA contact mutations confer a strong selection pressure to eliminate wild-type alleles, and that they result in an accelerated tumour progression and reduced therapeutic responsiveness.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9582015     DOI: 10.1038/sj.onc.1201690

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

1.  [Gene therapy with p53 tumor suppressors].

Authors:  A Dietz; D Esser; M Helbig; F X Bosch
Journal:  HNO       Date:  2003-04-15       Impact factor: 1.284

2.  rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy.

Authors:  Guang-Xia Chen; Li-Hong Zheng; Shi-Yu Liu; Xiao-Hua He
Journal:  World J Gastroenterol       Date:  2011-10-14       Impact factor: 5.742

Review 3.  Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma.

Authors:  Giovana R Thomas; Hari Nadiminti; Jacinto Regalado
Journal:  Int J Exp Pathol       Date:  2005-12       Impact factor: 1.925

4.  Frequent deletion of ING2 locus at 4q35.1 associates with advanced tumor stage in head and neck squamous cell carcinoma.

Authors:  Silvia S Borkosky; Mehmet Gunduz; Hitoshi Nagatsuka; Levent Bekir Beder; Esra Gunduz; Mahmoud A L Sheikh Ali; Andrea P Rodriguez; Mehmet Zeynel Cilek; Susumu Tominaga; Noboru Yamanaka; Kenji Shimizu; Noriyuki Nagai
Journal:  J Cancer Res Clin Oncol       Date:  2008-11-08       Impact factor: 4.553

Review 5.  Molecular mechanisms of head and neck cancer.

Authors:  Amit M Deshpande; David T Wong
Journal:  Expert Rev Anticancer Ther       Date:  2008-05       Impact factor: 4.512

6.  Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.

Authors:  David M Neskey; Abdullah A Osman; Thomas J Ow; Panagiotis Katsonis; Thomas McDonald; Stephanie C Hicks; Teng-Kuei Hsu; Curtis R Pickering; Alexandra Ward; Ameeta Patel; John S Yordy; Heath D Skinner; Uma Giri; Daisuke Sano; Michael D Story; Beth M Beadle; Adel K El-Naggar; Merrill S Kies; William N William; Carlos Caulin; Mitchell Frederick; Marek Kimmel; Jeffrey N Myers; Olivier Lichtarge
Journal:  Cancer Res       Date:  2015-01-29       Impact factor: 12.701

Review 7.  Molecular margins in head and neck cancer: Current techniques and future directions.

Authors:  Katelyn O Stepan; Michael M Li; Stephen Y Kang; Sidharth V Puram
Journal:  Oral Oncol       Date:  2020-07-20       Impact factor: 5.337

Review 8.  Molecular changes in the multistage pathogenesis of head and neck cancer.

Authors:  Brian J Park; Simion I Chiosea; Jennifer R Grandis
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 9.  Molecular pathogenesis of head and neck squamous cell carcinoma.

Authors:  David Hardisson
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-05-08       Impact factor: 2.503

Review 10.  Lessons learned from next-generation sequencing in head and neck cancer.

Authors:  Myriam Loyo; Ryan J Li; Chetan Bettegowda; Curtis R Pickering; Mitchell J Frederick; Jeffrey N Myers; Nishant Agrawal
Journal:  Head Neck       Date:  2012-08-21       Impact factor: 3.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.